Filing Flows

Filing Flows › aTYR Pharma (ATYR) › Who owns the stock

Who owns aTYR Pharma (ATYR) stock

82 funds reported aTYR Pharma (ATYR) shares in their latest 13F filings, worth $28.2M in all. The largest holder is Federated Hermes ($5.1M). Last quarter 39 funds added to their stakes and 58 cut them.

Largest holders of ATYR (13F)Largest holders of ATYR (13F)Federated Hermes$5.1MVanguard Group$3.9MVanguard Capital Management LLC$2.3MKalehua Capital Management LLC$2.1MGSA Capital Partners LLP$2.1MAQR Capital Management LLC$1.6MFMR LLC$1.5MBlackRock$1.1MJane Street Group, LLC$1.0MUBS Group AG$914K

Largest holders (13F)

FundSharesValueChangeQuarter
Federated Hermes8,509,678$5.1Mdecrease2026-06-30
Vanguard Group4,961,871$3.9Mdecrease2025-12-31
Vanguard Capital Management LLC3,808,091$2.3Mdecrease2026-06-30
Kalehua Capital Management LLC3,576,334$2.1Mnew2026-06-30
GSA Capital Partners LLP3,454,863$2.1Mincrease2026-06-30
AQR Capital Management LLC2,610,548$1.6Mincrease2026-06-30
FMR LLC2,471,418$1.5Mdecrease2026-06-30
BlackRock1,827,332$1.1Mdecrease2026-06-30
Jane Street Group, LLC1,721,297$1.0Mincrease2026-06-30
UBS Group AG1,531,151$914Kdecrease2026-06-30
Morgan Stanley1,343,636$802Kincrease2026-06-30
Two Sigma Investments, LP1,245,147$743Kincrease2026-06-30
Citadel Advisors LLC1,242,067$741Kincrease2026-06-30
Geode Capital Management, LLC1,177,020$703Kdecrease2026-06-30
Susquehanna International Group, LLP747,039$446Kdecrease2026-06-30

aTYR Pharma's latest quarter

aTYR Pharma, Q3 2025: revenue $190K, net loss $25.7M, operating cash flow −$20.5M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most ATYR stock?

By the latest 13F filings: Federated Hermes ($5.1M); Vanguard Group ($3.9M); Vanguard Capital Management LLC ($2.3M); Kalehua Capital Management LLC ($2.1M); GSA Capital Partners LLP ($2.1M).

What is the short interest in ATYR?

10,273,700 shares were sold short at the 2026-10-15 settlement, -20.32% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.